Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
KYMR Kymera Therapeutics
- 40.660
- +1.520+3.88%
Close Dec 20 16:00 ET
- 40.900
- +0.240+0.59%
Post 20:01 ET
2.63BMarket Cap-17.38P/E (TTM)
40.775High38.240Low1.15MVolume38.660Open39.140Pre Close46.28MTurnover2.64%Turnover RatioLossP/E (Static)64.77MShares53.27052wk High2.95P/B1.76BFloat Cap22.35052wk Low--Dividend TTM43.37MShs Float91.920Historical High--Div YieldTTM6.48%Amplitude9.600Historical Low40.382Avg Price1Lot Size
Kymera Therapeutics News
BTIG Initiates Coverage On Kymera Therapeutics With Buy Rating, Announces Price Target of $60
Kymera Therapeutics Initiated at Market Perform by BMO Capital
BMO Capital Initiates Kymera Therapeutics(KYMR.US) With Hold Rating, Announces Target Price $55
Cautious Optimism for Kymera Therapeutics: Hold Rating Amid Uncertainties in Innovative Protein Degradation Programs
Insider Sale: Director at $KYMR (KYMR) Sells 2,500 Shares
Kymera Upped to Overweight by Wells Fargo on Upcoming Data
Kymera International Acquires Coating Center Castrop GmbH
Wells Fargo Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Raises Target Price to $57
Express News | Wells Fargo Upgrades Kymera Therapeutics to Overweight, Raises Price Target to $57
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
Kymera Therapeutics (KYMR) Gets a Hold From Wells Fargo
There's Reason For Concern Over Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Price
Stephens Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $65
Kymera Therapeutics Price Target Announced at $65.00/Share by Stephens & Co.
Kymera Therapeutics Initiated at Overweight by Stephens & Co.
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $49
Express News | Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $49
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $53
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)